Showing results (11-20 of 33) with videos related to
Sort By:
Pageof 4
The American Journal of Cardiology|October 23, 1985
Effects of esmolol on cardiac function: evaluation by noninvasive techniquesA S Iskandrian, A H Hakki, A LadduEuropean Urology|January 1, 1992
Efficacy of terazosin in patients with benign prostatic hyperplasiaH Matzkin, M S Soloway, M C Rangel, et al.Journal of Clinical Pharmacology|May 1, 1992
Effect of age and dose on the incidence of adverse events in the treatment of hypertension in patients receiving terazosinB S Hosmane, C J Maurath, D C Jordan, et al.American Heart Journal|October 1, 1987
Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settingsP Turlapaty, A Laddu, V S Murthy, et al.Heart Failure Reviews|October 7, 2010
Pharmacologic modulation of parasympathetic activity in heart failureMonali Y Desai, Mari A Watanabe, Abhay A Laddu, et al.International Journal of Clinical Pharmacology, Therapy, and Toxicology|April 1, 1988
The electrophysiologic properties of esmolol, a short acting beta-blockerA M Greenspan, S R Spielman, L N Horowitz, et al.The American Journal of Cardiology|November 1, 1987
Electropharmacology of flestolol for supraventricular tachycardia without associated structural heart diseaseC Swerdlow, J Peterson, L B Liem, et al.The American Journal of Cardiology|April 19, 2014
Comparison of in-hospital outcomes for beta-blocker use versus non-beta blocker use in patients presenting with cocaine-associated chest painZaher Fanari, Kevin K Kennedy, Michael J Lim, et al.Clinical Pharmacology and Therapeutics|May 1, 1986
Tolerance and beta-adrenergic blocking activity of flestolol, a short-acting beta blockerP Turlapaty, J Burge, J Hulse, et al.Journal of Clinical Pharmacology|August 1, 1987
Hemodynamic effects of esmolol, an ultrashort-acting beta blockerJ Askenazi, P E MacCosbe, J Hoff, et al.Pageof 4